GBA Gene Mutation
8
4
4
3
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 8 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (8)
World Data on Ambroxol for Patients With GD and GBA Related PD
Ambroxol as a Disease-modifying Treatment in GBA-PD
The GBA Multimodal Study in Parkinson's Disease
LRRK2, GBA and Other Genetic Biomarkers in Eastern European (Ashkenazi) Jews With and Without Parkinson's Disease
Drug Discovery for Parkinson's With Mutations in the GBA Gene
Parkinson Disease and DBS: Cognitive Effects in GBA Mutation Carriers
High-Dose Ambroxol in GBA1-Related Parkinson
Evaluation of the Frequency and Severity of Sleep Abnormalities in Patients With Parkinson's Disease